BMO Capital raised the firm’s price target on Neurogene (NGNE) to $22 from $16 and keeps an Outperform rating on the shares. The firm notes that the company’s ASGCT presentations and the recent FDA earnings commentary gives it increased confidence in acceptance of non-placebo controlled trials, the analyst tells investors in a research note. Additional ASGCT presentations outline risk mitigation strategies which makes BMO more confident going forward, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene announces treatment intended to reverse HLH
- Cautious Hold Rating on Neurogene Due to Regulatory Uncertainty and Data Quality Concerns for NGN-401
- Neurogene downgraded to Neutral from Outperform at Baird
- Neurogene price target lowered to $45 from $50 at H.C. Wainwright
- Neurogene’s Promising Outlook: Strategic Focus on Safety and Efficacy Justifies Buy Rating